TY - JOUR
T1 - Cytokine gene polymorphisms in acute cellular rejection following living donor liver transplantation
T2 - Analysis of 155 donor-recipient pairs
AU - Kamei, Hideya
AU - Masuda, Satohiro
AU - Nakamura, Taro
AU - Ishigami, Masatoshi
AU - Fujimoto, Yasuhiro
AU - Ogura, Yasuhiro
AU - Oike, Fumitaka
AU - Takada, Yasutsugu
AU - Hamajima, Nobuyuki
PY - 2013/7
Y1 - 2013/7
N2 - Purpose: Despite improvements in immunosuppressive therapy, acute cellular rejection (ACR) remains an important cause of graft loss in patients undergoing liver transplantation. Recently, associations between cytokine gene polymorphisms in recipients and the occurrence of ACR have been reported. However, most studies did not investigate gene polymorphisms in donors or were limited by the number of cases investigated. Methods: We examined 155 living donor liver transplantation (LDLT) patients treated at Nagoya University or Kyoto University from 2004 to 2009. The following gene polymorphisms in recipients and donors were analyzed: tumor necrosis factor A (TNF-A) T-1031C, interleukin 2 (IL-2) T-330G, IL-10C-819T, IL-13C-1111T, and transforming growth factor B (TGF-B) T29C. Results: Forty-seven recipients (30.3 %) developed early ACR. Of the investigated gene polymorphisms, the IL-13 -1111C/C genotype in recipients was significantly associated with a higher incidence of ACR relative to the other two genotypes (OR = 2.64, 95 % CI 1.19-5.86, p = 0.017), while we showed the lack of association between investigated gene polymorphisms in donors and ACR incidence. Conclusion: The IL-13 -1111C/C genotype in recipients might be a risk factor for ACR in LDLT, and this might contribute to individualized immunosuppression strategies for recipients. On the other hand, the current study showed no associations of cytokine gene polymorphisms in donors with ACR incidence.
AB - Purpose: Despite improvements in immunosuppressive therapy, acute cellular rejection (ACR) remains an important cause of graft loss in patients undergoing liver transplantation. Recently, associations between cytokine gene polymorphisms in recipients and the occurrence of ACR have been reported. However, most studies did not investigate gene polymorphisms in donors or were limited by the number of cases investigated. Methods: We examined 155 living donor liver transplantation (LDLT) patients treated at Nagoya University or Kyoto University from 2004 to 2009. The following gene polymorphisms in recipients and donors were analyzed: tumor necrosis factor A (TNF-A) T-1031C, interleukin 2 (IL-2) T-330G, IL-10C-819T, IL-13C-1111T, and transforming growth factor B (TGF-B) T29C. Results: Forty-seven recipients (30.3 %) developed early ACR. Of the investigated gene polymorphisms, the IL-13 -1111C/C genotype in recipients was significantly associated with a higher incidence of ACR relative to the other two genotypes (OR = 2.64, 95 % CI 1.19-5.86, p = 0.017), while we showed the lack of association between investigated gene polymorphisms in donors and ACR incidence. Conclusion: The IL-13 -1111C/C genotype in recipients might be a risk factor for ACR in LDLT, and this might contribute to individualized immunosuppression strategies for recipients. On the other hand, the current study showed no associations of cytokine gene polymorphisms in donors with ACR incidence.
UR - http://www.scopus.com/inward/record.url?scp=84884355051&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84884355051&partnerID=8YFLogxK
U2 - 10.1007/s12072-013-9443-2
DO - 10.1007/s12072-013-9443-2
M3 - Article
AN - SCOPUS:84884355051
SN - 1936-0533
VL - 7
SP - 916
EP - 922
JO - Hepatology International
JF - Hepatology International
IS - 3
ER -